CollPlant Biotechnologies Ltd. (NASDAQ:CLGN – Get Free Report) was the target of a large increase in short interest in October. As of October 15th, there was short interest totalling 14,500 shares, an increase of 79.0% from the September 30th total of 8,100 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average trading volume of 12,100 shares, the short-interest ratio is presently 1.2 days.
CollPlant Biotechnologies Price Performance
Shares of CLGN traded up $0.12 during trading hours on Friday, reaching $3.97. 9,577 shares of the company’s stock traded hands, compared to its average volume of 9,524. The firm has a market capitalization of $45.50 million, a price-to-earnings ratio of -5.79 and a beta of 0.31. The business’s fifty day simple moving average is $4.79 and its two-hundred day simple moving average is $5.11. CollPlant Biotechnologies has a twelve month low of $3.76 and a twelve month high of $6.99.
CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) last announced its earnings results on Tuesday, August 20th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). CollPlant Biotechnologies had a negative return on equity of 65.98% and a negative net margin of 2,535.70%. The company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.70 million. On average, equities research analysts expect that CollPlant Biotechnologies will post -1.44 EPS for the current year.
Institutional Trading of CollPlant Biotechnologies
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the stock. EF Hutton Acquisition Co. I raised shares of CollPlant Biotechnologies to a “strong-buy” rating in a report on Monday, August 5th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of CollPlant Biotechnologies in a research note on Wednesday, August 21st.
Get Our Latest Analysis on CLGN
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
Further Reading
- Five stocks we like better than CollPlant Biotechnologies
- Find and Profitably Trade Stocks at 52-Week Lows
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Are Dividend Contenders? Investing in Dividend Contenders
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Options Trading – Understanding Strike Price
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.